“The purpose of this study is to assess the safety and tolerability (good and bad effects) and how prostate cancer responds to two different doses of the investigational study drug (ARV-766) in combination with Abiraterone in men with metastatic cRPC who have not received prior novel hormonal therapies.”
Anyone heard of or familiar with this clinical trial/study or the study drug (ARV-766)? As stated in my bio, I’m planning to participate if I pass the screening tests.
ARV-766 PROTAC: first results will be announced at 2024 ASCO congress next week
Cycle 1 of Clinical Trials
Phase 3 Clinical Trial 
Phase 1 trial participation Nurix NX-1607
